Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors
Phase 1
- Conditions
- Metastatic Solid TumorsTherapeutic area: Diseases [C] - Neoplasms [C04]MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104
- Registration Number
- CTIS2023-503425-18-00
- Lead Sponsor
- F. Hoffmann-La Roche AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 192
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method